{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-24-000025","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.384956+00:00","generated_at":"2026-06-02T21:31:21.904941+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance","bullets":["Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.","Adjusted EPS -$0.01 vs -$0.21 YoY; positive adjusted EBITDA $4M vs -$19M.","Revenue growth driven by Prenatal (+22%), Pharmacogenomics (+21%), Hereditary Cancer (+16%).","Announced sale of EndoPredict to Eurobio Scientific; retains U.S. license.","Reiterates FY2024 guidance: revenue $820-840M, adjusted EBITDA $20-30M, adjusted EPS $0.00-$0.05."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-24-000025","json":"https://secwatch.observer/filing/0000899923-24-000025.json","markdown":"https://secwatch.observer/filing/0000899923-24-000025.md","text":"https://secwatch.observer/filing/0000899923-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/0000899923-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/mygn-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:31:21.904941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"355db3fa41b4b9939abe9ab7f02864775203cf11","claim":"MYRIAD GENETICS INC reported first quarter ended March 31, 2024 results: revenue $202.2 million, net income $26 million, EPS $(0.29). Guidance reaffirmed.","evidence_excerpt":"Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000025/0000899923-24-000025-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$202.2 million"},{"label":"Net income","value":"$26 million"},{"label":"EPS","value":"$(0.29)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}